ProCE Banner Activity

Pooled Analysis of Cardiovascular Events From Clinical Trials Evaluating Acalabrutinib Monotherapy in CLL

Slideset Download
Conference Coverage
In a pooled analysis, cardiac AEs occurred in 17% of patients with CLL treated with acalabrutinib monotherapy a large majority of whom had preexisting risk factors.

Released: December 10, 2020

Expiration: December 09, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology